SS-31 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously at a consistent time. This concentrated dilution keeps standard doses within a single insulin syringe for convenience and accuracy.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
3. Gently swirl until fully dissolved (clear solution).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light; use within 4 weeks. At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in original sealed vial; keep dry and protected from light.
• Reconstituted: refrigerate at 2 to 8 °C immediately after mixing; use within 4 weeks for optimal stability.
• Avoid freeze-thaw: do not refreeze reconstituted solution; prepare aliquots if needed.
• Allow refrigerated vials to reach room temperature before opening to reduce condensation.

Supplies Needed

Plan based on an 8 to 12 week daily protocol with gradual titration.

Peptide Vials (SS-31, 10 mg each):

• 8 weeks (Standard, 5 to 10 mg/day): ~50 vials.
• 12 weeks (Standard maintenance at 10 mg/day): ~77 vials.
• 12 weeks (Advanced, escalating to 15 mg/day): ~105 vials.

Insulin Syringes (U-100, 1 mL):

• Per week (standard): 7 syringes (1/day). 8 weeks: 56. 12 weeks: 84.
• Advanced protocols with split injections may require 2 syringes per day for higher doses.

Bacteriostatic Water (30 mL bottles):

• 8 weeks (50 vials): 2 bottles. 12 weeks (77 vials): 3 bottles. Advanced (105 vials): 4 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 12 weeks: 168 swabs (2 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent

lipohypertrophy.

• Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.
• Mild injection-site reactions (redness, itching, transient discomfort) are the most common side effects

reported in clinical trials; these typically resolve within hours.

• Document daily dose, injection site, and any adverse reactions to maintain consistency.
• For doses requiring split injections (15 mg or above), space injections at least 2 inches apart on different

body regions.

How This Works

SS-31 (elamipretide) is a cell-permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure. By stabilizing cardiolipin-protein interactions, SS-31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues. Preclinical research demonstrated that SS-31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia-reperfusion injury, neurodegeneration, chronic kidney disease, and age-related muscle atrophy. In human clinical trials, SS-31 showed favorable safety and tolerability with no dose-limiting toxicities. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six-minute walk distance, leading to FDA accelerated approval in 2025.

Benefits & Side Effects

Observations from preclinical models and human clinical trials.

• Stabilizes mitochondrial membranes and optimizes electron transport chain function.
• Enhances ATP production and reduces pathological reactive oxygen species in metabolically active

tissues.

• Demonstrated functional improvements in Barth syndrome patients (increased muscle strength,

improved exercise capacity).

• Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and

age-related muscle atrophy.

• Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials.
• Injection-site reactions: mild to moderate redness, itching, or transient discomfort at injection site;

typically resolves within hours. Approximately 80% of patients in clinical trials experienced mild

injection-site reactions.

• No dose-limiting toxicities or serious adverse events directly attributed to SS-31 in published trials.
• Long-term safety data beyond 12 weeks remains limited; extended use requires monitoring.

Lifestyle Factors

Complementary strategies for best outcomes.

• Nutrition: emphasize mitochondrial cofactors including B-vitamins, CoQ10, magnesium, and alpha-lipoic

acid; maintain adequate protein intake.

• Exercise: combine resistance training with aerobic activity to stimulate mitochondrial biogenesis.
• Sleep: prioritize 7 to 9 hours of quality sleep to support cellular repair processes and mitochondrial

turnover through autophagy.

• Stress management: chronic stress increases oxidative burden.
• Avoid mitotoxins: minimize exposure to substances that impair mitochondrial function, including

excessive alcohol and environmental toxins.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Elamipretide: structure, mechanism of action, and therapeutic potential (Int J Mol Sci).
2. Cardiolipin-binding mechanism and mitochondrial membrane stabilization by SS-31 (Br J Pharmacology).
3. FDA grants accelerated approval to elamipretide (Forzinity) for Barth syndrome (FDA, 2025).
4. TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome (Genetics in Medicine).